Tesamorelin Dosage Chart: Clinical & Research Dosing

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It does not put growth hormone into your body. It signals your pituitary to release more of its own, in the same pulsatile rhythm it already uses.

Think of a furnace on a thermostat. Injecting synthetic HGH is like running a space heater at full blast all night: constant heat, no feedback, no off switch. Tesamorelin turns the thermostat up instead, so your own furnace burns hotter during its normal cycles and still shuts off when the room warms. Literally: tesamorelin amplifies your natural GH pulses while IGF-1 feedback keeps the axis regulated, which is why dosing stays fixed instead of climbing.

That mechanism explains the flat dose. In the pivotal trial, 2 mg daily raised IGF-1 and cut visceral adipose tissue by roughly 15% over 26 weeks in patients with HIV-associated central fat accumulation (Falutz et al., N Engl J Med, 2007, PMID 18057338). More was not tested as better; 2 mg was simply the dose that moved fat without breaking the feedback loop. It also explains why tesamorelin is dosed daily while HGH itself follows different rules, and why it behaves differently from the GHRP class covered in the tesamorelin vs sermorelin vs ipamorelin comparison.

One sentence of context first: only the HIV lipodystrophy dose is FDA-validated, and every other tier below is extrapolated from it by researchers and clinics.

The visceral fat numbers are the best documented. Across two pooled phase 3 trials, 2 mg daily reduced visceral adipose tissue by about 15-18% versus placebo over 26 weeks, and the fat returned after discontinuation (Falutz et al., J Clin Endocrinol Metab, 2010, PMID 20554713). A separate randomized trial found tesamorelin also reduced liver fat (Stanley et al., JAMA, 2014, PMID 25038357), later confirmed over 12 months in a dedicated NAFLD trial (Stanley et al., Lancet HIV, 2019, PMID 31611038).

If your only goal is body composition, the fat-loss-specific protocols, stacking options, and week-by-week expectations live in the dedicated tesamorelin dosage for fat loss guide. The regulatory picture, including what the approval does and does not cover, is in is tesamorelin FDA approved.

Research tesamorelin ships as lyophilized powder, usually in 2 mg, 5 mg, or 10 mg vials. Your syringe units depend entirely on how much bacteriostatic water you add. The peptide amount is fixed; the water only sets the concentration.

Walk through one row so the logic sticks. A 5 mg vial plus 2.5 mL of water gives 5 mg / 2.5 mL = 2 mg per mL. On a U-100 insulin syringe, 1 mL equals 100 units, so a 2 mg dose is a full 100 units and a 1 mg dose is 50 units. Add only 1 mL instead and the same vial becomes 5 mg/mL, so 2 mg shrinks to 40 units.

Write the concentration on the vial with a marker the moment you reconstitute. Full technique, from swabbing the stopper to aiming the water stream down the glass wall, is in the how to reconstitute peptides guide. To check your own numbers, run them through the peptide reconstitution calculator or convert any dose with the peptide unit converter.

Inject tesamorelin once daily, and pick a consistent slot. Two timings dominate real protocols: the Egrifta label pattern of a fixed daily time into abdominal fat, and the research habit of injecting 30 to 60 minutes before bed on an empty stomach.

The bedtime logic is physiological. Your largest natural GH pulse arrives during the first hours of deep sleep, and a GHRH analog amplifies pulses that are already firing. Food works against you here because elevated insulin and free fatty acids blunt GH release, so keep 2 to 3 hours between your last meal and the injection.

Cycle length depends on the goal. Visceral fat changes need patience: measurable reduction took 26 weeks in the phase 3 trials, and stopping reversed it, with visceral fat returning toward baseline during the off-treatment extension (Falutz et al., 2010, PMID 20554713). Liver fat needed 12 months to show its full effect (Stanley et al., Lancet HIV, 2019, PMID 31611038).

A practical research pattern is 12 weeks on, then 4 or more weeks off while you evaluate waist measurements and bloodwork. Tesamorelin's half-life is short, roughly 26 to 38 minutes, so the drug clears within hours even though its downstream IGF-1 effects persist for days; you can model this decay with the peptide half-life tracker. Between injections, keep the reconstituted vial refrigerated and follow the peptide storage guide, because a degraded vial quietly turns a 2 mg dose into an unknown one.

Tesamorelin needs no GLP-1 style titration ladder. The clinical dose starts at 2 mg on day one. Many researchers still run 1 mg for the first 1 to 2 weeks as a tolerance check for water retention, joint aches, and injection-site reactions, then step up to 2 mg. That is the entire ramp.

The expensive errors are concentration errors, not titration errors.

Mistake 1: carrying old syringe units to a new concentration. You finish a 5 mg vial mixed with 2.5 mL (2 mg/mL), where your 2 mg dose was 100 units. The next vial gets only 1 mL of water, making 5 mg/mL. Draw your usual 100 units and you inject 5 mg, 2.5 times the clinical dose, with the fluid retention, joint pain, and glucose spikes that scale with it. Fix: recalculate units every single time you reconstitute.

Mistake 2: dosing a 10 mg vial like a 2 mg vial. A 10 mg vial with 1 mL of water is 10 mg/mL. The habitual 100-unit draw now delivers 10 mg, five times the studied dose, in one injection. Fix: write mg/mL on the vial label before the first draw.

Mistake 3: ignoring glucose. Tesamorelin raised IGF-1 and nudged glucose measures in trials (Falutz et al., 2007, PMID 18057338), which matters if you are insulin resistant. Fix: baseline fasting glucose and IGF-1, then recheck at week 8 to 12, as outlined in the peptide safety guide.

Mistake 4: quitting at week 4 and calling it a failure. Visceral fat moved over 26 weeks in the trials, not four. If daily 2 mg injections do not fit your budget or patience, compare longer-acting alternatives in the tesamorelin vs ipamorelin breakdown instead of doubling the dose.